✦ LIBER ✦

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

✍ Scribed by Flaherty, Keith T.; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; O'Dwyer, Peter J.; Lee, Richard J.; Grippo, Joseph F.; Nolop, Keith; Chapman, Paul B.

Book ID: 119952423
Publisher: Massachusetts Medical Society
Year: 2010
Tongue: English
Weight: 830 KB
Volume: 363
Category: Article
ISSN: 0096-6762
DOI: 10.1056/NEJMoa1002011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Improved Survival with MEK Inhibition in

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

✍ Flaherty, Keith T.; Robert, Caroline; Hersey, Peter; Nathan, Paul; Garbe, Claus; 📂 Article 📅 2012 🏛 Massachusetts Medical Society 🌐 English ⚖ 157 KB

Analysis of BRAF Mutation in Primary and

Analysis of BRAF Mutation in Primary and Metastatic Melanoma

✍ Libra, Massimo; Malaponte, Grazia; Navolanic, Patrick M.; Gangemi, Pietro; Bevel 📂 Article 📅 2005 🏛 Landes Bioscience 🌐 English ⚖ 294 KB

Detection of BRAF V600 Mutations in Meta

Detection of BRAF V600 Mutations in Metastatic Melanoma

✍ Qu, Kevin; Pan, Qiulu; Zhang, Xi; Rodriguez, Luis; Zhang, Ke; Li, Hairong; Ho, A 📂 Article 📅 2013 🏛 American Society for Investigative Pathology 🌐 English ⚖ 527 KB

330 INVITED The Development of Vemurafen

330 INVITED The Development of Vemurafenib for BRAF-mutated, Metastatic Melanoma

✍ F. Borellini 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 38 KB

Combined BRAF and MEK Inhibition in Mela

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

✍ Flaherty, Keith T.; Infante, Jeffery R.; Daud, Adil; Gonzalez, Rene; Kefford, Ri 📂 Article 📅 2012 🏛 Massachusetts Medical Society 🌐 English ⚖ 528 KB

Combined BRAF and MEK Inhibition in Mela

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

✍ Flaherty, Keith T.; Infante, Jeffery R.; Daud, Adil; Gonzalez, Rene; Kefford, Ri 📂 Article 📅 2012 🏛 Massachusetts Medical Society 🌐 English ⚖ 528 KB

## Background Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with da braf e nib, a selective BRAF inhibitor, and trametinib, a